Highlights and Quick Summary
- EBITDA Margin for the quarter ending September 29, 2021 was 7.63% (a -17.87% decrease compared to previous quarter)
- Year-over-year quarterly EBITDA Margin increased by 370.99%
- Annual EBITDA Margin for 2020 was 2.97% (a -42.22% decrease from previous year)
- Annual EBITDA Margin for 2019 was 5.14% (a -444.97% decrease from previous year)
- Annual EBITDA Margin for 2018 was -1.49% (a -92.34% decrease from previous year)
- Twelve month EBITDA Margin ending September 29, 2021 was 7.42% (a 5.55% increase compared to previous quarter)
- Twelve month trailing EBITDA Margin increased by 137.06% year-over-year
Trailing EBITDA Margin for the last four month:
|29 Sep '21||29 Jun '21||30 Mar '21||30 Dec '20|
Visit stockrow.com/PGNY for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical EBITDA Margin of Progyny, Inc.Most recent EBITDA Marginof PGNY including historical data for past 10 years.
Interactive Chart of EBITDA Margin of Progyny, Inc.
Progyny, Inc. EBITDA Margin for the past 10 Years (both Annual and Quarterly)
Business Profile of Progyny, Inc.
Industry: Health Information Services
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.